Login / Signup

Somatostatin Receptor Subtype 4 Agonists for Potential Treatment of Alzheimer's Disease and Other Central Nervous System Disorders.

Ahmed F Abdel-Magid
Published in: ACS medicinal chemistry letters (2024)
The invention in this patent application relates to N -(pyrrolidine-3-yl or piperidin-4-yl)acetamide derivatives represented generally by formula 1. These compounds possess activities as somatostatin receptor 4 (SSTR4) agonists and may potentially be beneficial in the treatment of diseases or disorders, associated with SSTR4 such as Alzheimer's disease (AD) and other CNS disorders such as epilepsy and depression.
Keyphrases
  • cognitive decline
  • depressive symptoms
  • physical activity
  • combination therapy
  • preterm infants
  • sleep quality
  • climate change
  • human health
  • mild cognitive impairment